#393 ‒ AMA #85: A Guide to Medications and Supplements: Determining What to Take, What to Skip, and How to Know if They’re Working for You

Peter Attia opens the AMA by insisting that any medication or supplement decision starts with a crystal‑clear problem definition. He recommends turning vague goals like “more energy” into measurable metrics—such as lowering ApoB to a specific value or reducing sleep onset latency within a set timeframe. This framework forces a counterfactual analysis: what happens if nothing is done? By anchoring choices to objective data, listeners avoid the storytelling bias that fuels unnecessary supplement purchases and can evaluate true health impact and long‑term outcomes.

Next, Attia links the intended “job” of an intervention to its evidence threshold. Treatments aimed at disease cure demand randomized‑controlled trials, while marginal quality‑of‑life tweaks may settle for observational data. He stresses that baseline risk determines whether a relative risk reduction translates into meaningful absolute benefit. A drug that cuts relative risk by 30 % might only shave a few percentage points off actual event rates for low‑risk individuals. Side‑effects, financial cost, inconvenience, and opportunity cost all enter the risk‑tolerance equation for patients and informs shared decision‑making.

Finally, Attia offers a practical self‑experiment framework. Listeners should set a baseline, introduce the agent, and monitor predefined endpoints for a predetermined period, watching for both expected benefits and hidden downsides. He warns that most over‑the‑counter supplements suffer from poor quality control, contamination, and marketing hype, making the FDA’s limited oversight a red flag. Only a narrow group—such as high‑quality vitamin D, omega‑3s, and magnesium—passes his risk‑reward filter, and even these require periodic reassessment and possible discontinuation to maintain safety.